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Abstract
Background: The efficacy of anti-malarial drugs is assessed over a period of 28-63 days (depending on the drugs’
residence time) following initiation of treatment in order to capture late failures. However, prolonged follow-up increases the
likelihood of new infections depending on transmission intensity. Therefore, molecular genotyping of highly polymorphic
regions of Plasmodium falciparum msp1, msp2 and glurp loci is usually carried out to distinguish recrudescence (true failures)
from new infections. This tool has now been adopted as an integral part of anti-malarial efficacy studies and clinical trials.
However, there are concerns over its utility and reliability because conclusions drawn from molecular typing depend on the
genetic profile of the respective parasite populations, but this profile is not systematically documented in most endemic
areas. This study presents the genetic diversity of P. falciparum msp1, msp2 and glurp markers in selected sub-Saharan Africa
countries with varying levels of endemicity namely Malawi, Tanzania, Uganda, Burkina Faso and São Tomé.
Methods: A total 780 baseline (Day 0) blood samples from children less than seven years, recruited in a
randomized controlled clinical trials done between 1996 and 2000 were genotyped. DNA was extracted; allelic
frequency and diversity were investigated by PCR followed by capillary electrophoresis for msp2 and fragment
sizing by a digitalized gel imager for msp1 and glurp.
Results and Conclusion: Plasmodium falciparum msp1, msp2 and glurp markers were highly polymorphic with low
allele frequencies. A total of 17 msp1 genotypes [eight MAD20-, one RO33- and eight K1-types]; 116 msp2
genotypes [83 3D7 and 33 FC27- types] and 14 glurp genotypes were recorded. All five sites recorded very high
expected heterozygosity (HE) values (0.68 - 0.99). HE was highest in msp2 locus (HE = 0.99), and lowest for msp1 (HE
= 0.68) (P < 0.0001). The genetic diversity and allelic frequency recorded were independent of transmission
intensity (P = 0.84, P = 0.25 respectively. A few genotypes had particularly high frequencies; however the most
abundant showed only a 4% probability that a new infection would share the same genotype as the baseline
infection. This is unlikely to confound the distinction of recrudescence from new infection, particularly if more than
one marker is used for genotyping. Hence, this study supports the use of msp1, msp2 and glurp in malaria clinical
trials in sub-Saharan Africa to discriminate new from recrudescent infections.
Background
The efficacy of anti-malarial drugs in endemic areas is
assessed over a follow-up period of 28 to 63 days,
depending of the drug’s residence time in the organism,
following initiation of treatment. While a longer follow-
up allows capturing more late failures [1] the likelihood
of re-infection increases in a way that is dependent
upon the intensity of transmission in the study area.
Comparing molecular genotypic pattern of pre-treat-
ment (baseline) and recurrent infections provides a
means to help characterize the recurrent parasites as a
recrudescence, i.e. a true failure, or a new infection
(either from pre-existing liver infection or a newly estab-
lished infection from an infected mosquito bite), i.e. a
successful treatment. * Correspondence: kmugittu@ihi.or.tz
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genetic polymorphism. This phenomenon is exploited
for genetic finger printing and for assessing parasite
population dynamics. For instance, high polymorphism
has been shown in msp1, msp2 and glurp genes in dif-
ferent geographical locations in malaria endemic areas
[2-7]. The probability of a patient, particularly in areas
of intense transmission, to be newly infected with a
parasite possessing an identical genotype to the former
infection is low [8]. Therefore, comparing the genotypes
of the three loci at baseline and at the time of parasite
recurrence would be expected to discriminate between
recrudescent and new infections [8,9]. Numerous clini-
cal drug trials have applied this approach to correct the
outcomes of drug efficacy studies [10-17].
However, the discriminating power of different mar-
kers is dependent on the extent of allelic diversity and
on the frequency of each allele within the population
under study. Indeed, recurrent episodes after treatment
can be reliably classified as recrudescence or re-infec-
t i o n si ft h ef r e q u e n c i e so ft h emsp2, msp1,a n dglurp
alleles, as detected by the genotyping protocol employed,
are known. It is obvious that a second infection appear-
ing during follow-up after the first has been apparently
cleared can be erroneously classified as recrudescent if
some alleles predominate in the population or if hetero-
zygosity is low, because under these circumstances a
n e wi n f e c t i o nw o u l db em o r el i k e l yt os h a r et h es a m e
genotype as the baseline infection. This will lead to an
over-estimation of treatment failures and consequently
unnecessary treatment policy changes.
The allelic diversity of msp2 has been observed to be
high in some areas, such as in the Kilombero valley in
Tanzania (82 msp2 alleles) [2], Papua New Guinea (42
msp2 alleles) [18], Ghana (164 msp2 alleles) [19] and
Côte d’Ivoire (50 msp2 genotypes) [20]. Conversely,
there is very limited information on msp1 or glurp
diversity across sub-Saharan Africa. This study presents
the msp1, msp2 and glurp genetic diversity and allele
frequencies in five Sub-Saharan African countries with
different transmission intensities namely, Malawi,
Tanzania, Uganda, Burkina Faso and São Tomé.
Methods
Study area and design
This study is part of two artemisinin combination ther-
apy (ACT) trials that took place in sub-Saharan African
regions with different malaria transmission intensities as
detailed below;
(i) Randomized, double-blinded artemisinin-combi-
nation trials sponsored by the UNICEF/UNDP/
WORLD BANK/WHO Special Programme for
Research and Training in Tropical Diseases (WHO/
TDR) between 1999 and 2000 in Burkina Faso,
Gabon, The Gambia, São Tomé, Senegal, Uganda,
Malawi and Kenya. The drugs tested in these trials
were amodiaquine, sulphadoxine-pyrimethamine
(SP) or chloroquine (CQ) alone or in combination
with artesunate. Due to time and financial limita-
tions only a subset of samples were analysed from
only four of these countries (Malawi, Uganda, Bur-
kina Faso and São Tomé) and used in the current
study.
(ii) A trial conducted by the Ifakara Health Institute
(IHI) and Swiss Tropical and Public Health Institute
(Swiss TPH) in Tanzania in 1996. Drugs tested in
this study were CQ alone vs. artemether-lumefan-
trine (AL).
The study site characteristics, methodological and
clinical findings are described elsewhere [13,21,22]. For
all the studies ethical approval was obtained from rele-
vant local and external ethics committees. Prior to
recruitment, informed consent was obtained from the
children’s parents or guardians. Blood samples from par-
ticipant patients were collected on IsoCode™ Stix (in
WHO/TDR trials) or as whole blood (in IHI/Swiss TPH
trial) on day 0, 7, 14, 21 and 28. A total of 780 baseline
pre-treatment samples (Day 0) were randomly selected
for genotyping, n = 180 from each study site except
Tanzania (n = 60).
Molecular genotyping
DNA was extracted from IsoCode™ S t i x( a tI H I )b y
boiling (for the WHO/TDR trial samples) as described
by manufacturer or by the standard phenol-chloform
method (at Swiss TPH) from whole blood (for IHI/
Swiss TPH trial samples) and finally suspended in
50 μlo r3 0μl of double-distilled sterile water, respec-
tively. The template was kept frozen until needed. PCR
amplification of template DNA and analysis of region
II of glurp, central polymorphic region of msp2 (3D7
and FC27 allelic families), and block 2 of msp1 (K1,
MAD20 and RO33 allelic families) was performed in
accordance to the recently recommended genotyping
protocol [23] with minor modifications, i.e. the pri-
mary PCR amplification for glurp and msp2 was
duplexed whereas msp1 and all nested amplifications
were uniplexed.
The primary duplexed and uniplexed PCR amplifica-
tions of were carried out in 75 μl whereas all nested
reactions were uniplexed and done in 50 μlf i n a lr e a c -
tion volumes. The primary duplexed (glurp and msp2)
reactions contained 1x PCR buffer B (Firepol Solis
®),
1.57 mM MgCl2, 120 μMo fe a c hd N T P ,0 . 4u n i t so f
Taq DNA polymerase (Firepol Solis
®), 30 μM of each
oligonucleotide primer (Operon, Table 1) and 5 μlo f
template DNA.
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Page 2 of 10The nested glurp amplification final reaction volumes
contained 1x buffer B, 1.5 mM MgCl2,1 2 8μMo fe a c h
dNTP, 75 μM of each oligonucleotide primer, 0.4 units
of Taq DNA polymerase (Firepol Solis
®)a n d2μlo f
primary PCR product as a template whereas nested
msp2 reactions had 1x buffer B, 1.5 mM MgCl2, 200 μM
of each dNTP, 300 μM of each fluorescent labeled family-
specific oligonucleotide primers (Applied Biosystems)
and 2 μl of primary PCR product as a template.
The uniplexed primary msp1 final reaction conditions
were same as in msp2. The three nested msp1 family-
specific amplification for Ro33-, K1- and MAD20-
families each contained 1x PCR buffer B, 2 mM MgCl2,
200 μM of each dNTP, 0.4 units of Taq DNA polymer-
ase, 25 μM of each oligonucleotide primer and 2 μlo f
primary msp1 amplification product as a template.
Thermo cycling was done using the MJ Thermal Con-
troller PTC-100™ (MJ Research Inc. Watertown, USA).
Temperature cycling parameters were: initial denatura-
tion at 95°C for 5 minutes followed by 30 cycles of
denaturation at 94°C for 1 minute, annealing at 58°C for
2 minutes (for both uniplexed and duplexed primary
PCR amplification) or 59°C for 2 minutes (for msp1 and
glurp nested PCR) and extension at 72°C for 2 minutes
followed by 10 minutes of final extension at 72°C.
Nested PCR for msp2: initial denaturation was 94°C for
2 minutes followed by 30 cycles of denaturation at 94°C
for 30 seconds, annealing at 50°C for 45 seconds and
extension at 70°C for 2 minutes. The last extension
cycle was prolonged for 10 minutes.
The primary and nested PCR amplification of the
msp1 and glurp loci were carried out at IHI laboratory
but all gel electrophoresis and digital image analysis
were done at the Swiss TPH laboratory. For the msp2
locus, all primary amplification reactions were done at
IHI laboratories whereas all nested PCR amplification
and subsequent analysis were done in Basel and the
conditions were as described elsewhere [19].
Allele detection and estimation of molecular weight
The nested glurp and msp1 PCR products were sepa-
rated directly on 3% or 3.5% ethidium bromide-stained
agarose gels, respectively, visualized under UV illumina-
tion and photographed. Gel photographs were visually
examined to identify successfully amplified fragment. All
glurp and msp1 positive samples were separated again
using 1.5% or 2% agarose gels, respectively, and directly
analysed by a digitalized gel documentation system
where band sizing and molecular weight were calculated
by the AlphaEase
®FC software version 6.0.0 Alpha Inno-
tech. The fragments were then grouped into “bins” dif-
fering by 25 bp for msp1 a n d5 0b pf o rglurp.A l l
fragments falling within the limits of the bin were con-
s i d e r e dt ob e l o n gt ot h es a m eg e n o t y p e .B i n sw e r e
determined manually and allelic frequencies were calcu-
lated by Stata v 9.0 (Stata Corporation Inc, Texas USA
and Stat View version 5.0.1).
The nested msp2 amplification products were sepa-
rated in 1.5% agarose gel in order to identify positive
samples, which were subsequently prepared for capillary
electrophoresis analysis. Briefly, PCR products were
diluted with distilled water to the ratios 1:10, 1:20 and
1:30 according to the intensity of the bands in the
nested PCR product. This was followed by the addition
10 ul of a 1:40 fluorescent size standard ROX-500
(Applied Biosystems) consisting of 16 fragments ranging
for 50 -500 bp in length, dried and shipped to the Medi-
cal Research Center Genomic Facility-London, England)
for capillary electrophoresis. At the genomic facility,
samples were analyzed by automated 3730xls DNA ana-
lyzer and a GeneMapper
® software analyzer version 3.2.
(Applied Biosystems LTD) was used to determine the
size of PCR fragments, as previously described [19].
Analysis of msp2 raw data, allele calling according to
manually selected 3 bp bins and calculation of a cut off
and allelic frequencies was performed by dedicated soft-
ware designed at the Swiss TPH.
Allelic richness and diversity and mean multiplicity of
infection (MOI)
As a measure for genetic diversity, the expected het-
erozygosity (HE) was calculated by use of the formula
HE = [n/(n-1)] [(1-∑Pi
2)], where n = sample size, Pi =
Table 1 Name, sequence and amplicon sizes generated
by Plasmodium falciparum msp1, msp2 and glurp PCR
amplification primers
Gene Amplification Primer Primer sequence
msp1 Primary M1OR 5’cttaaatagtattctaattcaagtggatca 3’
MIOF 5’ctagaagctttagaagatgcagtattg 3’
Secondary MKR 5’gcttgcatcagctggagggcttgcaccaga 3’
MKF 5’aaatgaagaagaaattactacaaaaggtgc 3’
Secondary M1MR 5’atctgaaggatttgtacgtcttgaattacc 3’
M1MF 5’aaatgaaggaacaagtggaacagctgttac 3’
Secondary M1RF 5’taaaggatggagcaaatactcaagttgttg 3’
RO33R2 5’caagtaattttgaactctatgttttaaatcagcgta
3’
msp2 Primary S2 5’-gaaggtaattaaaacattgtc 3’
S3 5’-gagggatgttgctgctccacag 3’
Secondary S1TAIL
FW
5’-gcttataatatgagtataaggagaa 3’
M5-
FC27-RV
6FAM 5’-gcattgccagaacttgaa 3’
N5-3D7-
RV
VIC 5’-ctgaagaggtactggtaga 3’
glurp Primary GF3 5’acatgcaagtgtgatcctgaa 3’
GF4* 5’tgtaggtaccacgggttcttgtgg 3’
Secondary GNF 5’tgttcacactgaacaattagatttagatca 3’
Note: * used also for as reverse primer in the secondary amplification.
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Page 3 of 10allele frequency. The mean multiplicity of infection
(MOI) was calculated as the quotient of the total num-
ber of P. falciparum genotypes for each marker in a
particular country and the number of positive PCR
samples.
Results
Study profile
Out of 780 baseline (Day 0) DNA samples, 599 (76.8%)
were successfully amplified for msp1, 679 (87%) for
msp2 and 575 (73.7%) for glurp loci (Table 2).
Mean multiplicity of infection (MOI)
Table 3 shows mean MOIs calculated using data from
each of the three marker genes for each of the five
study countries. The mean MOI for msp2 loci was the
highest (2.24), followed by that for msp1 (1.48) and then
for glurp (1.4). The mean MOI values calculated for
msp1 and glurp were similar but substantially different
from those of msp2.
Genetic diversity and allelic frequency
The number of genotypes observed at each marker by
country is shown in Table 4. Seventeen (17) different
msp1 genotypes were observed, representing K1 (8 gen-
otypes), MAD20 (8 genotypes) and RO33 (1 genotype)
allelic families. The msp 1 fragment sizes ranged from
1 3 5b p-3 0 5b p .F i g u r e1s h o w st h ef r e q u e n c i e so f
msp1 genotypes by country. The majority of these geno-
types occurred at a frequency below 10%. However, four
genotypes from the K1 allelic family (176 bp-201 bp,
201 bp-2262 bp, 226-251 bp, 151-176 bp), two from the
MAD20 family (176 bp-201 bp and 201 bp-226 bp)
occurred above 10%.
The R033 family is considered to be monomorphic
with a predicted amplified fragment size of 215 bp.
However, the gel analysis software estimated the frag-
ment amplified from most samples to be between 180
bp - 210 bp. When a set of 6 samples representative of
these two sizes were sequenced, they were all found to
be 215 bp long.
The msp2 diversity and genotype frequencies for each
of the countries are shown in Figure 2. A total of 116
different msp2 genotypes (size range from 205 to 518
bp) were recorded at the 5 study sites, of which, 83/116
(71.6%) and 33/116 (28.4%) belonged to the 3D7 and
FC27 allelic families, respectively (Table 4). The fre-
quencies of individual msp2 genotypes were low with
96.5% occurring at a frequency ≤ 5%. Only four (3.5%)
genotypes, all belonging to the FC27 allelic family were
found at frequencies at or above 5%.
Fourteen (14) different glurp genotypes were detected
and their diversity across the countries is shown in
Figure 3. The allelic variants ranged between 650 bp
and 1,250 bp, and the majority (77.4%) occurred at fre-
quencies < 10%. Two genotypes, bin sizes 907 bp-957
bp and 957 bp-1,007 bp, had the highest frequencies,
20% in Uganda and 18% in Malawi, respectively.
Expected heterozygosity (HE) was calculated in order
to assess the discriminatory power of the three indivi-
dual markers. HE estimates the fraction of all parasites
that would be heterozygous for any of the three loci.
Table 5 shows generally very high HE values across the
five sites studies.
Discussion
Polymorphic regions from of the P. falciparum msp1,
msp2 and glurp loci have been selected as the recom-
mended markers for parasite genotyping in anti-malarial
drug trials and efficacy studies [23]. However, the para-
sites’ genetic profile has not been systematically docu-
mented in many malaria endemic countries. A large
number of archived P. falciparum positive pre-treatment
infections were genotyped in order to compare the
diversity and allelic frequencies for these three markers
among five geographical areas with different transmis-
sion intensities across sub-Saharan Africa; namely
Malawi, Tanzania, Uganda, Burkina Faso and São Tomé.
These blood samples were collected in the region during
two clinical trials (WHO/TDR and IHI/Swiss TPH) of
artemisinin-based combination therapy that were con-
ducted between 1996 and 2000. The findings from these
Table 2 DNA amplification success rate for each marker gene in baseline samples in 5 countries
Country Study year n PCR-positive samples
msp1 (%) msp2 (%) glurp (%)
K1 MAD20 RO33 Total
B*. Faso 2000 180 71 33 37 95 (53) 154 (86) 110 (61)
Malawi 2000 180 100 53 68 146(81) 145 (81) 135 (75)
São Tomé 2000 180 100 65 65 171 (95) 164 (91) 145 (81)
Tanzania 1996 60 48 30 10 50 (83) 56 (93) 45 (75)
Uganda 2000 180 100 41 27 137 (76) 160 (89) 140 (78)
Total 780 599(76.8) 679 (87) 575(73.7)
Note: * B = Burkina, S = Study.
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of this study was to determine whether the genetic
diversity of the markers or their suitability for PCR-cor-
rection of drug efficacy trials in endemic countries, var-
ied between countries. In addition, since the PCR-
corrected treatment failures in both of the above trials
were >10%, the study also aimed at validating these cor-
rections by assessing the Day 0 genotypic profile as
recommended [23].
Although Isocode stix were stored at room tempera-
ture over nine years, the majority (53 - 95%) of the
DNA samples could be amplified; with some unex-
plained variation unrelated to amplified fragment size
across the geographical sites. This molecular genotyping
study shows that on average the majority of the patients
were infected with more than one parasite genotype on
the day of admission. The mean MOI values were het-
erogenous across the different sites, being lowest in
Uganda, and highest in Burkina-Faso and Tanzania.
Mean MOI was highest for msp2 (2.24), followed by
msp1 (1.48) and was lowest for glurp (1.40) and the alle-
lic diversity followed a similar trend recording 116, 17
and 14 alleles, respectively. The allelic variants were spa-
tially distributed across the five Sub-Saharan African
countries. The differences in allele diversity between
msp2 on the one hand and msp1 and glurp on the other
are clearly attributable to the method used for DNA
fragment sizing. Indeed capillary electrophoresis used
for msp2 has a much higher power of resolution than
gel elecrophoresis and digitalized fragment sizing used
for msp1 and glurp [24]. However, since the genotyping
methods used were the same for all geographic sites, it
is possible to compare diversity of a given marker
between countries. Tanzania recorded the highest
genetic diversity, while Uganda recorded the lowest
diversity in all the three markers.
In the WHO/TDR trials [15], the crude post day-14
parasitological recurrence rate for all treatment groups
was 22% and was 89.7% for chloroquine alone and
13.6% for artemether-lumefantrine for the IHI-Swiss
TPH trial [21]. According to the recently adopted
recommendations for malaria genotyping [23], PCR-cor-
rected failure rates exceeding 10% would require deter-
mining MOI and allelic frequencies in order to confirm
the validity of the PCR-correction. Thus observation of
high MOI, high allele diversity and low allele frequen-
cies for all markers (especially msp2 whose fragments
were sized by the most accurate method) and study sites
are strongly indicative of the high discriminatory power
of this three-marker genotyping strategy. These findings
further validate the PCR-adjusted outcomes recorded
previously [15,21].
High genetic diversity and low allelic frequencies
have been reported previously from other sites that
differ substantially in transmission intensity: Gabon
[7], Uganda [10], Senegal [25], Burkina Faso [26] and
Honduras [27]. Nonetheless, three allelic variants of
msp1 (151-176 bp, 176-201 bp and 201-226 bp), four
of msp2 (wos12, wos3, K1-long and FC27-455) and five
of glurp (857-907 bp, 907-957 bp, 957-1007 bp, 1007-
1057 and 1057-1107 were recorded at frequencies
exceeding 5% in some of the study sites. Such fre-
quently occurring genotypes might lead to misclassifi-
cation of recurrent parasites in clinical trials and drug
efficacy studies. However, from the current data even
the most abundant genotype of glurp with a recorded
allelic frequency of 20%, the probability of acquiring a
new independent infection of the same genotype by
chance equals the square of the allelic frequency. This
probability of 4% for a reinfection with the same geno-
type is not very high for a single genotyping marker; it
would be even much lower when all three markers
were genotyped.
Table 4 msp1, msp2 and glurp alleles observed in the 5 study countries
Country Number of genotypes per allelic-family/locus
msp1 msp2 glurp
K1 (%) Mad20 (%) RO33 (%) Total 3D7 (%) FC27 (%) Total
B**. Faso 8(53.3) 6(40) 1(6.7) 15 71 (73.2) 26 (26.8) 97 14
São Tomé 8(50) 7(43.7) 1(6.3) 16 60 (80) 15 (20) 75 14
Malawi 7(53.8) 5(38.5) 1(7.7) 13 53 (76.8) 16 (23.2) 69 13
Uganda 5 (50) 4 (40) 1 (10) 10 38 (77.6) 11 (22.4) 49 10
Tanzania 8(50) 7(43.8) 1(6.20) 16 57 (78.1) 16 (21.9) 73 13
Total* 88 1 17 83 33 116 14
Note: * Number of observed allele not sum of alleles, ** B = Burkina.
Table 3 Mean Multiplicity of infection recorded using
msp1, msp2 and glurp loci in the 5 study countries
Malawi B. Faso Sao Tome Tanzania Uganda Average
msp1 1.03 1.40 1.30 2.50 1.18 1.48
msp2 1.52 3.03 2.00 3.48 1.17 2.24
glurp 1.01 1.86 1.01 1.84 1.29 1.40
Study participant were children 0 to 5 years old at all sites.
Note: B = Burkina.
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Page 5 of 10It should be noted that the blood samples analysed
were collected more than nine years ago, hence the
genetic profiles described might no longer accurately
represent the current situation. Nonetheless, this study
provides important genetic background data in these
areas. The strength of the present study hinges on four
major factors: (i) the large number of baseline samples
that, (ii) were collected from five countries with different
levels of transmission intensity, (iii) use of automated
DNA sizing methods to remove investigator bias and
 
 
Figure 1 msp1 allelic frequency (%) by country. Most of the genotypes occurred below 10%. Four K1-family genotypes and two MAD20-
family genotypes occurred above 10%. Note; only genotypes with frequency ≥ 4% (0.04) are labeled.
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ducts, and (iv) comparative analyses across countries
could be conducted, because the data was obtained
using the same amplification protocol.
One of the factors that directly impinge on the utility of
genotyping protocols in drug efficacy studies is that of bin
size selection. For this study, as for all previous studies,
the bin sizes for msp1 or glurp fragments have been set
rather arbitrarily. The lengths of the repeat units, whose
number varies between the different allelic variants, was
taken into account to set bin width of 25 bp and 50 bp for
msp1 and glurp, respectively. In contrast, msp2 fragments
   
WHITE= Fc27 
GREY = 3D7  
Figure 2 msp2 allelic diversity and frequency (%) by country. Only three genotypes, all from FC27 family occurred at of above 5%. Note;
only genotypes with frequency ≥ 4% (0.04) are labeled.
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Page 7 of 10were sized by capillary electrophoresis with 3 bp bin width
that quite obviously represents the smallest size difference
possible in a coding region. In previous studies, different
bin widths were used, for example, [28] used a conserva-
tive bin width of 40 bp for msp1 and msp2, whilst [10]
used bin sizes of 10 bp for msp1 and msp2 and 20 bp for
glurp. In addition to these variations in bin width, the dif-
ferent fragment sizing methods employed by different
researchers make it difficult to compare data for a particu-
lar marker between studies.
 
Figure 3 glurp allelic diversity and frequency (%) by country. Only genotypes with frequency ≥ 4% (0.04) are labeled.
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Page 8 of 10Another drawback of this genotyping protocol is the
variability in the electrophoretic migration of a given
DNA fragment between gels, and indeed between differ-
ent regions of the same gel. This is clearly illustrated in
our observations of variable RO33 fragment sizes by
digital gel documentation, despite the fact that these
fragments were confirmed to be of the same size (215
bp) by sequencing. It is most likely that such spurious
variability will also occur for variants of the other msp1
allelic families, and maybe even to a greater extent in
the much larger glurp fragments. Thus, the quality and
value of the data obtained from binning of alleles across
different gels depends largely on gel quality (e.g. “smil-
ing effect” or unequal loading of gel slot) and on the
accuracy of image digitization. Electrophoretic variability
is a potential problem when one wishes to establish the
frequencies of each allelic variant. When sizing is done
across different gels, binning through an image analyzer
might be more prone to error than doing it by eye,
especially when samples are run side by side. This error
observed when comparing fragments from different gels,
is highly unlikely to affect the validity of the genotype
pattern comparisons of baseline and recurrent infec-
tions, on which PCR correction is based, because the
amplified products from these samples are usually
migrated in the gels side-by-side and, therefore, with a
much reduced chances of variability. For such compari-
sons, detection of size differences can either be done
visually or through an image analysis programme.
Admittedly, visual analysis also poses some degree of
subjectivity: at what level of difference in migration does
one say that two bands are different, especially when
they differ in quantity and consequently intensity and
thickness in the gel.
Ultimately, the ability to distinguish between two allelic
variants depends directly on the resolution of the method
used to analyse the amplified fragments. At present capil-
lary electrophoresis offers the best solution, because it
provides accurate and reproducible estimates of DNA
fragment lengths with a resolution power down to a few
base pairs difference. It is highly likely that the msp1 and
glurp fragments amplified in the course of this study in
fact encompassed a larger repertoire of distinct allelic
variants than those resolved by simple agarose gel elec-
trophoresis. By the time this study was done, only msp2
capillary electrophoresis protocol was described [19].
Now protocols for msp1 [29,30] and glurp [24] have been
developed and all three markers can be analyzed and
allele diversity/frequency compared more accurately.
Conclusion
The P. falciparum msp1, msp2 and glurp markers used
for PCR-correction of treatment outcomes in the con-
text of drug clinical trials or efficacy studies in endemic
areas appear to be highly polymorphic and to have low
allelic frequencies across sub-Saharan countries with
varying transmission intensities. These observations
reinforce the value of these genotyping markers in clas-
sifying recurrent post-treatment P. falciparum episodes
as recrudescence or new-infections. However, these
findings strongly suggest that standardized protocols
should include optimal methods for fragment size esti-
mation and bin width determinations. This will further
enable and simplify data comparison between sites/stu-
dies. With the expanding access to ACT and current
changes in malaria epidemiology, the P. falciparum
msp1, msp2 and glurp allele frequency/genetic diversity
should be monitored regularly to ensure the reliability
of the PCR-adjusted treatment outcome.
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